Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

28 comunicati stampa

Guarda tutti i comunicati
01/04/2026
Mercato del lavoro
Industria
Scienza
Fitness
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
01/04/2026
Mercato del lavoro
Industria
Salute
Tecnica
Biotecnologia
Fitness
Farmaceutica
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
30/03/2026
Mercato del lavoro
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
30/03/2026
Mercato del lavoro
Industria
Salute
Biotecnologia
Scienza
Farmaceutica
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
27/03/2026
Industria
Oncologia
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
27/03/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Mercato del lavoro
Industria
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
23/03/2026
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
23/03/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sanità
Mercato del lavoro
Industria
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
28/02/2026
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
09/01/2026
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0